DRUG · Unmapped registry intervention
INT131 besylate
Find medicine records ·
Find other trials using this name
Clinical trial
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
NCT00631007
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Pioglitazone HCl
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
InteKrin Therapeutics, Inc.lead sponsor
Mapped research locations
DallasTexas, United States3MiamiFlorida, United States3ChicagoIllinois, United States2San AntonioTexas, United States2CincinnatiOhio, United States2TampaFlorida, United States2Los AngelesCalifornia, United States1BaltimoreMaryland, United States1AtlantaGeorgia, United States1ClevelandOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00631007 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.